Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities

Recursion Pharmaceuticals Inc RXRX expanded its existing strategic collaboration in fibrosis with Bayer AG BAYRY.
The expanded collaboration will include Recursion's inferential search capabilities based on its growing maps of human cellular biology.
Recursion and Bayer may now work on more than a dozen programs in a total of relevance to fibrotic disease.
All projects will remain subject to the previously agreed upon economics, where each potential program could generate more than $100 million in commercial milestone payments plus royalties on future sales.
In the expanded collaboration, the Company will leverage the Recursion Map to explore hundreds of billions of biological relationships that span whole-genome genetic perturbations, hundreds of soluble factors, and hundreds of thousands of pharmacological perturbations.
Price Action: RXRX shares are up 5.47% at $18.69 during the market session on the last check Monday.